 | New innovative report discusses how the global IVD market will develop in light of commercial opportunities and high technological potential
In vitro diagnostics constitute an important, growing healthcare industry and market, one that is increasingly biotechnological and closely aligned with pharma. In vitro diagnostic (IVD) tests provide essential information about physiological states, aiding diagnoses and choice of treatments. IVD’s usefulness in drug development – especially via biomarkers – constitutes a major advance, and an expanding market opportunity. Our new report - In Vitro Diagnostics: Market Analysis 2009-2024 - analyses the global IVD market comprehensively. This new study provides sales forecasts and discussions of emerging technologies and commercial opportunities, along with other information that you require.
|
|
 | OTC pharma is influenced by changes in consumer spending - but significant commercial opportunities for OTC switching will drive market expansion worldwide – our new report explains
General economic trends worldwide will affect the over-the-counter (OTC) pharma market from 2009 onwards, with both market restraints and opportunities present. In this new report - The Global OTC Pharmaceutical Market 2009-2024 – visiongain notes that Rx-to-OTC switching and the continuing importance of emerging pharma markets will drive OTC sales growth from 2009 onwards. Our forecasts reveal that the OTC pharma market will grow significantly next decade. This report explains where future OTC switching will occur, providing you with the information that you need to understand the current OTC market and its future prospects. The potential of this market remains significant, despite general economic uncertainty, visiongain asserts.
|
|
 | Monoclonal antibodies in cancer therapy – significant commercial opportunities with developing technologies and innovative products – our new report explains prospects
Monoclonal antibody-based therapies for cancer are a thriving part of the biotechnology sector, as our new market report explains. The oncology market continues to expand worldwide, with high demand for more-efficacious and better-tolerated cancer therapies. The monoclonal antibodies oncology market has been growing at a significant rate and holds high potential for continued growth in both developed and emerging geographical markets. Currently, new technologies are removing some of the drawbacks that monoclonal antibody therapies have experienced. Leading pharma companies are already investing heavily in monoclonal antibody technologies. Monoclonal antibodies with great commercial potential are in the oncology pipeline, as our new report - Monoclonal Antibodies in Cancer Therapy 2009-2024 – also explains.
|
|
 | Pharmacovigilance gaining in importance after Vioxx problems – our new report analyses post-marketing assessment from the present onwards
Pharmacovigilance has been expanding in recent years, as companies are required to monitor drug safety post launch. Drug safety issues, such as those raised by Vioxx earlier this decade, have led to increased risk-averseness by regulators, with greater post-marketing assessment of drugs. Many regulatory agencies require detailed pharmacovigilance, with companies bearing extra costs, our new report also observes. Healthcare payers, prescribers and patients have high expectations from pharmacovigilance. They want thorough information - on adverse reactions and overall drug safety - upon which to make informed judgements. Pharmacovigilance is now being called upon to produce clear results, expressed openly. What will those trends mean for pharmacovigilance, from the perspectives of major stakeholders, including the pharma and biotech industries? Where is pharmacovigilance heading? What regulatory measures will continue, and which new processes will emerge? This new report - Pharmacovigilance 2009: Present Challenges and Future Goals - explains how that field will develop from the present onwards.
|
|
 | There is great demand for lower-cost biological drugs: commercial and regulatory developments will make biosimilars and follow-on biologics a success – our new report explains how Revenues for biologic drugs reached approximately $125bn in 2008. Patents on most current biologics have expired or will expire during the period 2009 to 2024. In addition, there is mounting pressure from governments, insurers and patients’ groups to reduce costs of pharmaceuticals. Biologic drugs - noted as some of the most-expensive medicines - are major targets for cost savings. The developments facilitating follow-on biologics are gaining momentum, with significant commercial opportunities emerging - as our new report explains. Recently Merck & Co. established a new biosimilar (follow-on biologic or biogeneric) development division; other major pharmaceutical companies plan to follow suit. In March 2009, three new bills on follow-on biologic legislation were introduced to the US Congress. Biosimilars are entering an important period of development. Is your company prepared for the opportunities and threats this will create? The new visiongain report - Biosimilars and Follow-On Biologics: The Global Outlook 2009-2024 - provides you with essential information to understand this rapidly-emerging market. |
|
 | Stem cell technologies – changes to US regulations to give exciting new hopes and potentially vast commercial opportunities – brand new indepth studyStem cells represent one of the most promising medical breakthroughs of all time, as our new market report explains. Currently, in 2009, the new US administration is lifting some major restrictions on stem cells technologies. This developmental obstacle now removed, all types of stem cells are available for expanding the therapeutic and commercial potentials, as our new report Stem Cells – The Hype & Hope – World Analysis 2009-2024 explains. Based upon the cells that create and renew all tissues potentially, stem cell therapies could revolutionise the treatment of disease, especially through tissue and organ replacement. Stem cells could provide revolutionary treatments for conditions from diabetes to multiple sclerosis, and from myocardial infarction to chronic obstructive pulmonary disease, amongst many others. Stem cell lines could also change the way pharmaceutical companies assess new chemical entities during R&D. |
|
 | The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. The World Health Organization estimates that over 2.5 million people suffer from multiple sclerosis worldwide. The prevalence and onset of MS in children and adults is expected to rise steadily. Global sales for MS therapies will rise accordingly, due to epidemiological, healthcare and commercial drivers. In this new market-based study - The Global Multiple Sclerosis Market 2009-2024 – we show and explain those trends in detail. This report will provide you with the analytical information that you need to understand current trends and future directions in the MS market area, the successful drugs being introduced and where the future successful growth of the market lies. |
|
 | The world statins market is changing, with patent expires and maturity of the landmark product Lipitor (atorvastatin). Statins are at the forefront of strategies to combat dyslipidaemia, being pivotal in the prevention of coronary heart disease. Consequently, those drugs are one of the most widely-prescribed and most lucrative sectors of the pharmaceutical industry, with total revenues exceeding $26 billion in 2008. Importantly, the world statins market is poised to undergo a period of rapid and dynamic change, with the generic statin sector growing particularly strongly in the years ahead. When will annual sales of generic statins exceed those of branded statins? Which branded statin will continue to achieve year-on-year sales growth during the coming waves of generic competition? Statins: The World Market, 2009-2024 answers these vital questions – amongst others - and provides the essential information that you need to take advantage of opportunities in the changing statin drugs market from 2009 onwards. |
|
 | This brand new in-depth market analysis examines the current and future prospects of the inflammatory bowel diseases (IBD) market. The world market for intestinal anti-inflammatories was worth over $2400 million in 2008, and had grown at 9% over the previous year.The value of other types of drugs used to treat IBD, including immunosuppressants and monoclonal antibodies, approached $12000m. Visiongain predicts the market for intestinal anti-inflammatories and IBD drugs to continue expanding, based on rising disease rates and evolving diagnostic methods. Currently, IBD is under-diagnosed, especially in developing countries. As governments and health services address chronic illnesses like IBD, this market will expand into previously untreated regions. Continuing studies and surveys indicate that IBD is spreading globally, and has an especially high prevalence rate in India. In addition, the Latin American countries experienced 14% sales growth last year, and are set to account for an increasingly large share of the world market in years to come. |
|
 | Obesity has been described as a 'public health time-bomb'. In 2005, the World Health Organization estimated that approximately 400 million individuals are obese. Prevalence of obesity is rising worryingly in many countries, despite campaigns emphasising the link between being overweight and contracting diabetes. This new report - Anti-Obesity Treatments 2009-2024 – explains those trends in commercial terms. In two of the largest national markets for anti-obesity treatments - the US and UK - over 20% of the population are seriously overweight. Obesity is a major risk factor in a number of other serious disorders, particularly diabetes and heart disease. Importantly, the financial burden of obesity and its associated conditions - both direct and indirect costs - are vast. Obesity is a serious, chronic condition with an emerging market for therapeutic products, as we show in this study. High socioeconomic costs and increasing prevalence are inspiring government initiatives to deal with the problem, with obesity becoming one of the most prominent global health concerns worldwide. Visiongain recognizes the contribution of drugs in this important emerging market, as diet and exercise are frequently not successful alone. We predict that new classes of drugs will invigorate the market - driving total sales in the next decade. In this report you will find out about those treatments, especially their sales potential. |
|
 | Incidence and prevalence of diabetes mellitus are increasing worldwide, in line with lifestyle changes and population aging. In particular, the rising prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities. As discussed in this new visiongain report - World Diabetes Market Analysis, 2009-2023 - The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. Governments and other healthcare providers around the world are investing in health education, diagnosis and treatments for this chronic, debilitating - but controllable - disorder. |
|
 | Smoking is the leading cause of preventable death in the world. The effects of smoking represent a global pandemic of enormous proportions. Currently-marketed smoking cessation aids typically lack high levels of efficacy in practice and are associated with marked side-effects. There are clear market opportunities for novel, more-efficacious and safer smoking cessation agents, in both prescription and OTC forms. |
|
 | The global market for ophthalmic pharmaceuticals is a large and profitable segment of the healthcare market, with ophthalmic sales of over $10bn in 2007. The recent therapeutic and commercial success of Lucentis has increased the number of blockbuster ophthalmic drugs and highlighted the lucrative commercial rewards on offer in this sector. Which will be the blockbusters of the future? This cutting-edge visiongain report provides the answer – and other essential information that you need to understand the ophthalmic pharmaceutical sector. |
|
 | This new market analysis by visiongain is to examine the current and future prospects for the world dermatological market. The world dermatological market generated total sales revenues of over $18bn in 2007. Visiongain predicts that this market area will expand further, increasing its total revenues significantly based on expansion of the market for modern drugs to treat skin disorders in developing countries, most notably China, India and Brazil. This report will outline the developments and explain their significance. |
|
 | The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970's. The leading healthcare biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other healthcare biotech companies catching up. The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market. Our new report - Top-10 Biotech Companies - Market Outlook, 2008-2023 - will help you to understand those developments and their significance. That report provides valuable commercial information on this exciting industry that no healthcare company should ignore. |
|
 | The generics market remains a major growth area in the global healthcare market. That growth has been partly driven by cost-containment in several national healthcare sectors, with governments seeking to promote the use of generic products over higher-priced originator products. The global generic pharmaceuticals market was worth over $100bn in 2007, with market growth noticeably higher that that of the overall pharmaceutical market. Our new report - World Generics Market, 2008-2013 - will help you to understand the key developments in this sector and their significance, from the present looking forward. The report provides valuable commercial information on this exciting sector, one that no pharmaceutical company or related organisation can afford to ignore. |
|
 | The global pain market generated total sales of $34bn in 2007 – but what will the figures be in the next 5 and 10 years? This report tells you.The pain market has marked strengths and advantages, but is also limited by problems and concerns. The market will be driven by new drugs and reformulations of existing ones – but which drugs will be most successful? The incidence of pain is increasing rapidly, what some experts call a pain epidemic – so the opportunities available to an additional blockbuster drug is significant. The prevention and treatment of pain is already one of the highest priorities for healthcare authorities in the world, yet for mature markets pain drug sales have fallen. However, visiongain believes that this market has strong growth potential, despite the prospect of generic competition for leading branded products. |
|
 | The global addiction market is significantly undervalued. The world’s population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides an in-depth analysis of the current state of the market for addiction therapy drugs, from the present looking forward. It covers the major therapy areas of smoking cessation, obesity, drug addiction and alcohol dependency. In addition, this study forecasts how your market will grow and develop, both quantitatively and qualitatively, during the period 2008-2023. |
|
 | The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in revenues in 2007, the GI disorders market competes consistently with cardiovascular diseases and oncology for the top 3 therapeutic areas in terms of market value. In 2007, this sector contributed seven blockbuster drugs, four of which ranked among the top 20 highest revenue generating prescription drugs in the world. However. the market is now mature, with well-established treatments now nearing the end of their patent life. So can you and your company continue to benefit from this market? Are you in a position to capture new profitable shares of the market? |
|
 | Last year, the Japanese pharmaceutical market was the second largest in the world, with a value of $58.5bn. However, Japan’s market has experienced growth at a much lower rate than the other major pharmaceutical markets. It is at a key stage in its development. You need to take notice of these changes. |
|
 | Visiongain predicts that there is great potential for the women’s reproductive disorders therapeutics market from present onwards, as this new report Women’s Reproductive Disorders Therapeutics, 2008-2018 shows.Oral Contraceptive MarketThe systemic hormonal contraceptive market is currently a $7bn market, with hormonal oral contraceptives dominating the market for many years. The oral pills are increasingly facing competition from other routes of delivery. With patent expiration, several companies have begun manufacturing generic products. Hormonal contraceptives for women have become the benchmark for the safety and effectiveness of birth control methods. |
|
 | Investors are turning their attention to antiviral drug discovery because there is a renewed recognition of the promising opportunities in this $20bn market. Twenty years from the inception of focused antiviral drug research, there are 8 blockbuster drugs currently on the market. Its double-digit growth makes it a standout segment within the general anti-infective therapeutic class. You should be maximizing your opportunities in this market. The opportunities for success are there now, you should capitalize on them immediately. |
|
|
 | - Includes Top 10 Therapy classes for biotech- Also Top 10 products in the biotech sector The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970’s. The leading biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other biotechnology companies catching up. The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market. |
|
 | The revenue for world contract manufacturing business in 2007 was approximately $30bn, with a growth rate of 6% from 2006. The technical expertise and cost savings offered by contract manufacturing organisations (CMOs) make them increasingly essential to you and your organisation. Greater emphasis has been put on European CMOs to leverage low-cost contract manufacturing markets, such as those existing in India and China, to enhance cost efficiency. Many CMOs in Europe have turned to biotech services as a means of avoiding competition with lower-cost API companies based in developing countries. In common with European service providers, North American CMOs are adopting a dynamic approach. Also, they are providing other services, such as packaging, logistics and marketing support. Are you taking advantage of the opportunities available? This unique report will guide you and inform you on how to benefit from the options - you should take the opportunity today. |
|
 | In 2007, the world market for bone metabolism disorder pharmaceuticals generated sales of over $10bn - how much of this market have you captured?The majority of this market consists of the fast-expanding osteoporosis segment, a disease with high incidence and under-treatment at present. The bone metabolism market is competitive and progressive, facing generic competition amongst its top-selling drugs. Nevertheless, market growth will be driven by aging populations worldwide and the entry of novel therapies during the years ahead. In Osteoporosis & Bone Metabolism Disorders, 2008-2023, visiongain forecasts that the bone metabolism disorder market will increase - but by just how much? Order the report today to find out.. |
|
 | Pfizer is the world's largest and most profitable pharmaceutical company. Its pharmaceutical division generates sales of $44671m in 2007. Pfizer is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. Pfizer's prominence is due to the company having nine blockbuster products, seven market leaders and strong products in all the major therapeutic categories. How can you compete with them? Which areas are the exposed in? Find out today. |
|
 | This brand new report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and pressure from an ever-aggressive generics industry, the segment of monoclonal antibodies therapeutics is thriving and growing at a double-digit rate. Therapeutic Monoclonal Antibodies 2008-2023 shows how monoclonal antibodies are a leading product of biotechnology, being increasingly used in therapy. Currently, monoclonal antibodies are playing an important role in the treatment of cancer, autoimmune and inflammatory disorders. Therapeutic monoclonal antibodies boast one of the most active and promising pipelines in the pharmaceutical industry. |
|
 | The global clinical trials business is worth an estimated $50bn in 2008, with a growth of rate of 10%. The market will show considerable growth in the future, as this visiongain report, Global Clinical Trial Business 2008-2018, explains in detail. In recent years, the nature of clinical trials has changed considerably. An increased emphasis has been placed on cost-effectiveness of pharmaceutical R&D, as well as increased productivity to maintain the high output of recent years. Consequently, the pharmaceutical industry has witnessed rapid expansion of outsourced clinical services in both the West and in developing nations, most notably India and China. |
|
 | The UK government have told kidney cancer patients that new drugs cannot be offered on the National Health Service. Roche's Avastin, Bayer's Nexavar, Pfizer's Sutent and Wyeth's Torisel were not cost-effective. The drugs -- known generically as bevacizumab, sorafenib, sunitinib and temsirolimus -- should therefore not be a treatment option for advanced and/or metastatic kidney cancer, NICE said. |
|
 | The major problem facing the Wholesale & Distribution industry is its low profit margin which is in the region of only 1-2%. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. As generics are priced lower than their branded counterparts, the actual dollar profit on them taken by W&D companies, for their movement, is reduced. In the light of this, other key factors such as new pricing and distribution models are also discussed in more detail. |
|
 | This brand new report examines the commercial prospects for in vitro diagnostics (IVD) in the global healthcare market. Technological solutions are playing an increasingly important role in both clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, current developments in diagnostics – especially molecular diagnostics - are paving the way towards the long-held goal of personalised medicine, to the benefit of patients, companies and healthcare providers. Developments in IVD also receive encouraging support from regulators such as the FDA. Visiongain believes that some of the greatest opportunities ever available for diagnostics companies are now there to be seized, with important sales, licensing and partnership developments from the present onwards. |
|
 | In 2007, Amgen Inc - the world’s largest biotechnology company - achieved total sales of $14.7m, despite a turbulent year marked by regulatory, pricing and reimbursement issues. Amgen has now firmly established itself as a Top-20 international pharmaceutical company. According to sales data for 2007, Amgen is also ranked as the 11th largest pharmaceutical company worldwide based on total sales value. This is a remarkable achievment for a biotechnology company founded in 1980. |
|
 | Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market. |
|
 | The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry’s leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. Importantly, the report forecasts the overall Indian pharmaceutical market from 2008 to 2023, as well as that of many important market segments. Other key metrics are also included throughout the report. This is your opportunity to gain critical insight into the potential and inner workings of one of the world’s most important healthcare markets from the present onwards. |
|
 | In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has repeatedly maintained steady growth over the past 5 years, crowding out the yearly revenues of other lipid-regulating blockbuster drugs: Merck& Co’s Zocor and Zetia, Astrazeneca’s Crestor, Abbott’s Tricor and Bristol Myers Squibb’s Pravacol. |
|
 | This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains. |
|
 | In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments. This brand new blood diseases treatments report breaks down therapies into four main groups:• Antithrombotics• Anti-anaemics• Clotting Factors• Others |
|
 | Which current or future therapies will drive the sleep disorders market from 2008 to 2018?What is the patient identification rate for each of the therapeutic areas?What is the present state of the disease awareness?What R&D opportunities exist for ‘new comers’?Which key companies are involved in the market?This report will tell you. The report focuses on the market for following sleep disorders:• Insomnia• Restless legs syndrome (RLS) • Narcolepsy and • Obstructive Sleep Apnoea / Hypopnea Syndrome (OSAHS) |
|
 | The generic industry is a fast evolving market; with significant lucrative opportunities. The generic market is structurally set to experience high growth potential. That wave is partly driven by cost-containment in several national healthcare sectors and partly by the need for governments to promote the use of generic products over high-priced originator products without compromising quality.In 2006, the global generics market attained strong revenues of approximately $65bn, up by 12% in comparison with $58bn in 2005. However, during the same period, the Top Ten leading generic suppliers generated total revenues of $27.9bn, up by a growth rate of 34%. The Top Five Companies within that sector experienced significant revenues, with market growth largely driven by significant commercial activities, key Mergers and Acquisition (M&A) and launch of new product in the leading markets. |
|
 | This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008 to 2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as the different drug classes. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. In the light of this, including other factors, visiongain predicts this market to decline in revenues – but which products will suffer most? How can you fight this generic competition? The antibacterial drug market generated revenues of $30274m in 2006 – but what will it be in 2013? |
|
 | This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments and strategies. The respiratory market generated revenues of $30503m in 2006, but what will it be in 2013? Which year the market will reach its peak? |
|
 | The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in 2012? This report will tell you. This in-depth market analysis examines prospects for antipsychotic drugs right through to 2012, including sales forecasts for leading products. The antipsychotics market will face decreasing growth throughout the forecast period, due to the patent expiry of leading blockbuster drugs. Safety concerns over the current antipsychotics along with high prices, will also contribute to decreased growth in this market. |
|
 | The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most popular and recognised brand on the market. Furthermore, high revenues are predicted by visiongain for the top three ED drugs, with Cialis reaching blockbuster status by 2007. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. The purpose of this market analysis by visiongain is to examine prospects for Erectile Dysfunction (ED) drugs from 2007-2022, including sales forecasts for leading pharmaceutical products. |
|
 | Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as “in-life” testing or “live” licensing. Those proposals involve cumulative testing of the drug throughout its lifecycle. The industry would continually test drugs with smaller, more focused clinical trials. If a trial shows efficacy and safety, a live license would be given, allowing the company to market the drug in a limited manner. Already, the FDA and the EMEA have shown favourable interest in such developments - amongst other amendments to current practice. |
|
| Migraine is a serious neurological disorder characterised by recurrent headaches, varying in severity and frequency. Accounting for the loss of over 100 million working days in the US alone, the economic cost and social impact of migraine is significant. Furthermore, the people most susceptible to migraine are those within their most productive years (22-55), causing both personal and professional disruptions and a significant burden on healthcare services. |
|
| Most skin disorders are not fatal but most people are affected globally. The revenue of dermatological market in 2006 was $16bn, which is a 5.1% when compared with 2003. The common skin disorders include acne, dermatitis, psoriasis, rosacea, urticaria and hair loss. Due to the aesthetic awareness increases in Western countries, botulinum toxin and other cosmetic treatments become more and more popular. |
|
| Alzheimers disease (AD) is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stake holders. With the grey population being the single most influencial factor in driving the economic growth within this sector, Visiongain believes the real market of the AD industry still remains untapped. |
|
| The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from Multiple Sclerosis (MS). With the present global population growing to an unprecedented height of 6.5 billion in 2005 and growth rate anticipated to reach 7.6 billion by 2020, the prevalence and onset of MS in children and particularly adults is expected to rise exponentially. |
|
| The market for hypertensives - led by the angiotensin II antagonists - is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or high blood pressure, is a worldwide epidemic: by 2025 visiongain predict that worldwide there will be more than 1.5 billion sufferers of this disease. Modern lifestyles, such as poor diet and lack of exercise, are the main contributory factors to elevated blood pressure. Consequently, the incidence and prevalence of hypertension are increasing rapidly in both developed and developing countries. |
|
| Diabetes affects approximately 246 million people worldwide and this number is increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. You cannot afford to ignore this market. To ignore this report when your competitors are reading it, would be a mistake. I urge you to read this report today. |
|
| The global pain pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 4.56% to 2012. Visiongain's latest report, "The Global Pain Pharmaceutical Market 2007-2022 ", explains just how this market will experience growth over the medium term future. The report also highlights forecast for 2022, so that you and your company can make longer term plans. |
|
| - Do you know what the next major blockbuster will be?- In the year 2000, when visiongain first produced their Blockbuster Drug market report there were 55 blockbuster drugs – now there are over 100. |
|
| Visiongain believe that the market for non-opioid drugs is the fastest growing segments in pain management with a CAGR of 8.12% for the period 2006-2012. The brand new report entitled “The Global Non-Opioid Market in Pain Management” has highlighted a number of innovative pipeline developments that are set to shape the industry over the medium term. |
|
 | Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease in the US, Maladie de Charcot in France and Motor Neuron Disease (MND) in the UK is a progressive neuromuscular disease characterised by the progressive degeneration of motor nerve cell in the brain (upper motor neurons) and spinal cord (lower motor). To date there is no cure for ALS. Present day medical management of the disease through the combinatorial use of medications and advancements in state-of-art technological devices for nutrition and breathing, have markedly increased the survival rate of ALS sufferers. |
|
 | Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities. In particular the large pharmaceutical companies Pfizer, sanofi-aventis, Eli Lilly & Company and Merck & Co all have substantial investment in the RNA/DNA therapy products market. With Merck & Co in particularly showing its faith in the future potential of this market by taking the gamble of acquiring the specialist RNAi company Sirna, towards the end of 2006. |
|
 | "By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found". For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities. |
|
 | Cigarette smoking is the most important source of preventable and premature morbidity worldwide. Currently, the number of smokers across the globe is estimated at 1.3 billion. Political moves are leading to national bans of smoking in public places, with the long-term aim to reduce the cost to the health sector. But what will be the short-term spending on smoking cessation therapies? |
|
|
 | Marinol®, Cesamet®, Sativex ® and Rimonabant are all commercially-marketed cannabinoids. They treat a variety of conditions from weight-loss to pain relief. The introduction of cannabinoids into the pharmaceutical marketplace has begun, and attitudes to the drugs are changing. This increased acceptance will lead to greater market penetration, and the importance of the area will be seen with the first cannabinoid reaching blockbuster status before the end of the decade. |
|
 | With the recent Alzheimer's Association International Conference suggesting a new era of hope for sufferers of the illness, drug trials have shown some enlightening discoveries. |
|
| Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest pharma markets, by 2012. As generations of people become more obese and consume increasingly poor diets then so too will the number of people suffering from these disorders rise. |
|
 | "Teva has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global pharmaceutical industry," finds visiongain report.Just some of the recent headlines surrounding Teva:- Court rules against Teva in patent dispute – May 11th - Teva gets tentative ok for generic of Eli Lilly’s Gemzar – May 8th- Teva Announces Approval and Shipment of Generic Omnicef – May 14th- Teva loses Merck generics race to U.S. rival Mylan - May 14th |
|
 | Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 11.11 per cent to 2012. This report explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints. |
|
